Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharma cuts Gvoke copay amid Covid-19

Xeris Pharmaceuticals Announces $0 Copay for Gvoke PFS for People With Diabetes

Xeris Pharmaceuticals Reinforces the Importance of GVOKE PFS for People With Diabetes

Xeris Pharmaceuticals, Inc. Just Reported Earnings, And Analysts Cut Their Target Price

Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q4 2019 Results - Earnings Call Transcript

Xeris Pharmaceuticals EPS misses by $0.08, beats on revenue

Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates

Xeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress

Xeris Pharmaceuticals Q4 EPS $(1.23) Misses $(1.13) Estimate, Sales $1.6M Beat $660K Estimate

Earnings Scheduled For March 11, 2020

The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study

Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for

The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020

The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Xeris Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares

Mizuho Maintains Buy on Xeris Pharmaceuticals, Lowers Price Target to $18